

Impact of COVID-19 on Clinical Studies

July 2021

The logo for acornai, featuring the word in a white, lowercase, sans-serif font. The letter 'o' is replaced by a stylized yellow and green graphic that resembles a drop or a leaf.

acornai

Impact of COVID-19 on Clinical Trials

50-80%

Peak decline in enrollment in clinical trials

30%+

Increase in missed visits for on-going studies at height of pandemic


~0%

Data Verification rates in April and May

Source of data: Medidata's Insights Data Warehouse

Investigator Response


Survey of Study Coordinators and Investigators; August 2020



Source: COVID-19 and Clinical Trials: The Medidata Perspective, Release 8.0

Trajectory of the Recovery

Subject Accrual in Clinical Trials - Percent of 2019 Baseline



Source of data: Medidata's Insights Data Warehouse

Industry Response - Data and Technology

Deploy Analytics

- Shift toward more agile approach to study management
- Updated approach to scenario planning and risk assessments



Rethink Data Capture

- Decentralization - Tele-visits, eConsent, eCOA, Patient portals
- Tokenization and links to RWD
- Synthetic Control Arms

Maintain Quality & Supply

- Risk Based Management and targeted Source Data Verification
- Remote Source Review
- Direct to patient supply